Assessment of APOE in Atypical Parkinsonism Syndromes

Marya S. Sabir, BSc[1], **Cornelis Blauwendraat, PhD**[1], **Sarah Ahmed, BSc**[1], **Geidy E. Serrano, PhD**[2], **Thomas G. Beach, MD, PhD**[2], **Matthew Perkins, BSc**[3], **Ann C. Rice, PhD**[4], **Eliezer Masliah, MD**[5], **Christopher M. Morris, PhD**[6], **Lasse Pihlstrom, MD, PhD**[7], **Alexander Pantelyat, MD**[8], **Susan M. Resnick, PhD**[9], **Mark R. Cookson, PhD**[5], **Dena G. Hernandez, PhD**[5], **Marilyn Albert, PhD**[8], **Ted M. Dawson, MD PhD**[8,10,11,12], **Liana S. Rosenthal, MD**[8], **Henry Houlden, MD, PhD**[13], **Olga Pletnikova, MD**[14], **Juan Troncoso, MD**[14], and **Sonja W. Scholz, MD, PhD**[1,8,†]

[1]Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

[2]Civin Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA

[3]Michigan Brain Bank, University of Michigan Medical School, Ann Arbor, MI, USA

[4]Virginia Commonwealth University Brain Bank, Virginia Commonwealth University, Richmond, VA, USA

[5]Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

[6]Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

[7]Department of Neurology, Oslo University Hospital, Oslo, Norway

[8]Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[9]Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA

[10]Neuroregeneration and Stem Cell Programs, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[11]Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[†]Correspondence to: Sonja W. Scholz, MD, PhD; Neurodegenerative Diseases Research Unit | National Institute of Neurological Disorders and Stroke | National Institutes of Health; 35 Convent Drive, Room 1A-215; Bethesda, MD 20892-3707, USA. sonja.scholz@nih.gov | Tel.: +1 (301) 451-1623.

AUTHORS' ROLES

Research Project: A. Conception (SWS), B. Organization (SWS), C. Sample Contributors (GES, TGB, MP, ACR, EM, CMM, LP, AP, SR, MRC, DGH, MA, TMD, LSR, HH, OP, JT), D. Execution (MSS, CB, SA, SWS). Statistical Analysis: A. Design (MSS, CB, SWS) B. Execution (MSS). C. Review and Critique (MSS, CB, SWS). Manuscript: A. Writing of the first draft (MSS), B. Review and Critique (CB, SA, GES, TGB, MP, ACR, EM, CMM, LP, AP, SR, MRC, DGH, MA, TMD, LSR, HH, OP, JT, SWS).

DISCLOSURE STATEMENT

The authors report no conflicts of interest.

¹²Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA

¹³Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

¹⁴Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD, USA

Abstract

Atypical parkinsonism syndromes are a heterogeneous group of neurodegenerative disorders that include corticobasal degeneration (CBD), Lewy body dementia (LBD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The *APOE ε4* allele is a well-established risk factor for Alzheimer's disease; however, the role of *APOE* in atypical parkinsonism syndromes remains controversial. To examine the associations of *APOE ε4* and *ε2* alleles with risk of developing these syndromes, a total of 991 pathologically-confirmed atypical parkinsonism cases were genotyped using the Illumina NeuroChip array. We also performed genotyping and logistic regression analyses to examine *APOE* frequency and associated risk in patients with Alzheimer's disease (n=571) and Parkinson's disease (n=348). *APOE* genotypes were compared to those from neurologic ally healthy controls (n=591). We demonstrate that *APOE ε4* and *ε2* carriers have a significantly increased and decreased risk, respectively, of developing Alzheimer's disease (*ε4:* OR: 4.13, 95% CI: 3.23-5.26, $p = 3.67 \times 10^{-30}$; *ε2:* OR: 0.21, 95% CI: 0.13-0.34; $p = 5.39 \times 10^{-10}$) and LBD (*ε4:* OR: 2.94, 95% CI: 2.34-3.71, $p = 6.60 \times 10^{-20}$; *ε2:* OR = OR: 0.39, 95% CI: 0.26-59; $p = 6.88 \times 10^{-6}$). No significant associations with risk for CBD, MSA, or PSP were observed. We also show that *APOE ε4* decreases survival in a dose-dependent manner in Alzheimer's disease and LBD. Taken together, this study does not provide evidence to implicate a role of *APOE* in the neuropathogenesis of CBD, MSA, or PSP. However, we confirm association of the *APOE ε4* allele with increased risk for LBD, and importantly demonstrate that *APOE ε2* reduces risk of this disease.

Keywords

1. INTRODUCTION

The prevalence of age-related neurodegenerative diseases is a growing public health concern.[1] There exists a critical, unmet need for unraveling the genetic architectures that underlie neurodegenerative disorders. Identifying and validating pathogenic molecular defects can inform targets for drug-discovery efforts and disease-modifying interventions. Atypical parkinsonism syndromes are a diverse group of progressive neurological disorders characterized by the presence of parkinsonism in addition to clinical features considered atypical for Parkinson's disease (PD), such as early falls and/or early cognitive impairment.[2] The accurate clinical diagnosis of atypical parkinsonism disorders remains a major challenge as a result of broad phenotypic variability and the overlap with mimic syndromes.

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are characterized pathologically by the presence of neuronal and glial tau-positive inclusions, while multiple system atrophy (MSA) and Lewy body dementia (LBD) are defined by abnormal accumulation of aggregated α-synuclein as glial cytoplasmic inclusions and as neuronal Lewy bodies, respectively.[3,4] Interestingly, AD co-pathology is observed in approximately 65 to 90% of LBD patients, placing LBD along a clinicopathological continuum between PD and AD.[5,6,7,8]

Advances in modern genomic technologies have been key to the systematic dissection of the molecular etiology of neurodegenerative diseases. These efforts have revealed overlapping risk loci among atypical parkinsonism syndromes and other neurodegenerative diseases clearly suggesting that these diseases are etiologically related. Dysregulation of lipid metabolism/homeostasis has been ascertained as a contributor of degenerative disorders.[9,10] The *ε4* allele of apolipoprotein E (*APOE*), a well-established lipid metabolism and cholesterol transport gene, is known to be a major genetic risk determinant for sporadic, late-onset AD and LBD.[11,12] Allelic dose effects for this gene have been observed among AD cases: a single copy of the *ε4* allele imparts a three-fold risk of developing disease, while subjects with an *ε4/ε4* genotype demonstrate an approximate eight-fold increase in disease risk.[11,12] The *ε4* allele is also associated with a significantly decreased age at disease onset and decreased survival in a dose-dependent manner.[11,13,14] On the other hand, the *APOE ε2* allele has been reported to have a protective effect in late-onset AD. Despite this, the role of the *ε2* allele in LBD and other atypical parkinsonism disorders remains unclear.[15–18] To address this question, we investigated the allele frequencies of *APOE* in four pathologically-confirmed cohorts of atypical parkinsonism in addition to AD and PD patients. We compared our findings to neurologically healthy controls.

2. MATERIAL AND METHODS

2.1 Study Subjects

Brain tissue and/or blood samples were obtained from eighteen North American and European research centers and brain banks (Supplementary Table 1). All participants gave written, informed consent for *post mortem* brain or blood donation. A total of 1,910 neurodegenerative disease patients of European ancestry and 591 neurologically healthy controls over the age of 50 were included (Table 1). The neurodegenerative disease cases included: AD (n=571), PD (n=348), LBD (total n=525; dementia with Lewy bodies (n=468) and Parkinson's disease dementia (n=57)), MSA(n=223), PSP (n=202), and CBD (n=41). All cases were diagnosed using consensus pathologic criteria.[19–24]

2.2 NeuroChip Array Genotyping and Quality Control

Genomic DNA was extracted from frozen brain tissue or blood using standard phenol-chloroform extraction techniques. Genotyping was performed using the NeuroChip (Illumina, San Diego, CA, USA), a versatile microarray that is comprised of a tagging backbone (n=306,670 variants) and 179,467 variants of custom "neuro" content.[25] NeuroChip genotyping was conducted following the manufacturer's protocol as described elsewhere.[25] The data were exported from GenomeStudio using the Illumina-to-PLINK

module 2.1.4 and imported into PLINK version 1.90.[26] Quality control procedures were performed, and only samples with call rates > 95%, lack of contamination (i.e. passing heterozygosity threshold of < 0.15), concordance between reported and genotypic sex, relatedness based on PIHAT metric < 0.125, and European ancestry individuals based on the 1000 Genomes Project were included in the study.[27]

2.3 *APOE* Allele Genotyping

Genotype calls of two *APOE* single nucleotide polymorphisms, rs429358 and rs7412, were used to determine the *APOE* status of each sample. The combination of genotypes for rs429358 (C/T) and rs7412 (C/T) defines the three allelic variants of *APOE:* epsilon 2 (ε2), epsilon 3 (ε3), and epsilon 4 (ε4). These three allelic variants produce six genotypes, ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4. Validation of accurate *APOE* genotype calls using NeuroChip compared to standard Taqman genotyping has been previously described.[25]

2.4 Statistical Analysis

Association of *APOE ε2* and *ε4* alleles with risk of neurodegenerative disease (i.e.; AD, PD, CBD, LBD, MSA, and PSP) compared to controls was evaluated using PLINK version 1.90 logistic regression models, adjusted for sex and age (i.e. age at death for pathologically-confirmed samples or age at specimen collection for clinically-defined control samples). Survival analyses were performed for each cohort using log-rank tests as implemented in the R "survival" and "survminer" packages. Only samples for which age of death information was available were included in these analyses (217/218 controls, 568/571 Alzheimer's disease cases, 523/525 LBD cases, 101/223 MSA cases, 202/202 PSP cases, 41/41 CBD cases).

3. RESULTS

We demonstrated that *APOE ε4* carriers (genotypes: *ε2/ε4, ε3/ε4,* and *ε4/ε4)* had a statistically significant increased risk of developing AD (OR: 4.13, 95% CI: 3.23-5.26, $p = 3.67 \times 10^{-30}$) and LBD (OR: 2.94, 95% CI: 2.34-3.71, $p = 6.60 \times 10^{-20}$). Both of these results surpassed the Bonferroni threshold for multiple comparisons (Table 2). In contrast, carriers of the *APOE ε2* allele, as defined by *ε2/ε2* and *ε2/ε3* genotypes, had a significantly decreased risk of developing AD (OR: 0.21, 95% CI: 0.13-0.34; $p = 5.39 \times 10^{-10}$) or LBD (OR: 0.39, 95% CI: 0.26-0.59; $p = 6.88 \times 10^{-6}$) (Table 2). There were no significant associations of *APOE ε4* and *ε2* with altered risk of developing CBD, MSA, PSP, or PD (Table 2, Supplementary Table 2). Additionally, a dose-response association between increasing *APOE ε4* allele dose and reduced survival was observed in AD ($p < 0.0001$) and LBD ($p = 0.0022$); the association with PSP did not surpass the Bonferroni threshold (Supplementary Figure 1).

4. DISCUSSION AND CONCLUSIONS

The *APOE ε4* allele has been widely and consistently implicated in the pathogenesis of AD and LBD.[28–32] The main objective of this study was to determine the frequency and risk of disease associated with the *APOE ε4* and *ε2* alleles in pathologically-confirmed atypical

parkinsonism subjects compared to neurologically healthy individuals. We confirmed the well-known effect of *APOE* on AD and LBD risk. In addition, we also compared autopsy-confirmed AD and PD cohorts to controls. We found that *APOE ε4* carrier status is significantly associated with increased risk of developing AD and LBD, while *APOE ε2* carriers have a decreased relative risk of developing these degenerative dementias. A prior study of *APOE ε2* in clinically-diagnosed DLB patients also demonstrated a protective *ε2* effect.[17] Recently, Dickson *et al.* reported that *APOE ε4* is associated with greater severity of Lewy body pathology independent of Alzheimer's disease pathology.[33] Interestingly, another recent study demonstrated similar decreases in methylation at the *APOE* locus in *post mortem* brain tissues of neuropathological pure LBD and AD suggesting that this epigenetic alteration may also be contributing to disease risk.[34]

Our data indicate that *APOE* is not a risk factor for PD nor MSA or for the tauopathies CBD and PSP. Our results confirmed previous studies of *APOE* in PD and MSA.[35–40] A genome-wide association study (GWAS) performed on a small cohort of CBD also found no association of *APOE* with CBD.[41] Recently, a study of 134 CBD cases found no significant associations of *ε2* or *ε4* with disease risk.[42] The role of *APOE* variants in risk of developing PSP has been controversial.[37,38,43,44,45,46] A higher frequency of *APOE, ε2* allele, but not *ε4* allele, in PSP was found in a Japanese cohort.[47] The first PSP GWAS, including 1,150 autopsy-confirmed cases, demonstrated that the *ε4* frequency is reduced in PSP.[48] A recent study by Zhao and colleagues of a series of 994 PSP patients found that *APOE ε2 ε2* carriers have a significantly increased risk of developing disease (OR=4.41).[42] Similarly, our study shows a higher frequency of *APOE ε2/ε2* carriers in PSP (1.5%) versus controls (0.8%), but no significant association of the *ε2* allele with risk of disease. Additionally, possession of the *APOE ε4* allele has not been shown to affect age of disease onset in MSA or PSP.[37]

A notable strength of this study is the use of large, pathologically-proven cohorts of atypical parkinsonism syndrome patients. This approach effectively eliminates diagnostic uncertainty due to heterogeneous clinical presentations and possible presence of mimic syndromes.

There are a number of limitations to this study. First, age information was not available for 134 subjects and most of the patients (122/134) were within the MSA cohort. Second, although our CBD cohort consisted of only 41 subjects, previous non-GWAS studies investigating *APOE* allele frequencies in CBD have been limited to 18 patients or fewer.[43,49,50,51] We acknowledge that our CBD cohort has only low power for identifying significant associations, and thus the results of the *APOE* analysis in this cohort should be interpreted with caution. Additionally, it is possible that our clinically-defined controls (n=373/591 subjects) may develop a neurodegenerative disease later in their life. To counter this limitation, logistic regression analyses performed with inclusion of only pathologically-confirmed controls mirrored the results in Table 2.

Taken together, our findings did not implicate *APOE ε4* as a major genetic risk determinant for atypical parkinsonism syndromes, including CBD, MSA, and PSP. In contrast, we replicate association of the *APOE ε4* allele and risk for LBD, and importantly demonstrate that possession of the *ε2* allele is associated with a lower relative risk. Additional functional

studies are required to elucidate the biological mechanism underlying this effect. Our findings support the notion of overlapping pathogenetic mechanisms between AD and LBD. Further investigation of other genetic loci associated with the spectrum of neurodegenerative diseases, particularly of AD- and PD-related loci, is essential for improving the diagnostic, prognostic, preventative and therapeutic management of atypical parkinsonism syndromes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

REFERENCES

1. World Health Organization. Neurological Disorders: Public Health Challenges. World Health Organization; 2006.

2. Scholz S, Bras J. Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders. Int J Mol Sci. 2015;16(10):24629–24655. [PubMed: 26501269]

3. Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469–491. [PubMed: 25549971]

4. Spillantini MG, Goedert M. Synucleinopathies: past, present and future. Neuropathol Appl Neurobiol. 2016;42(1):3–5. [PubMed: 26819143]

5. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60(10):1586–1590. [PubMed: 12771246]

6. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102(4):355–363. [PubMed: 11603811]

7. Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord. 2014;20(5):525–529. [PubMed: 24637124]

8. Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(Pt 10)3005–3014. [PubMed: 23065790]

9. Sultana R, Perluigi M, Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med. 2013;62:157–169. [PubMed: 23044265]

10. Bleasel JM, Wong JH, Halliday GM, Kim WS. Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol Commun. 2014;2:15. [PubMed: 24502382]

11. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921–923. [PubMed: 8346443]

12. Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118. [PubMed: 23296339]

13. Schächter F Faure-Delanef L, Guénot F, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 1994;6(1):29–32. [PubMed: 8136829]

14. Christensen K, Johnson TE, Vaupel JW. The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet. 2006;7(6):436–448. [PubMed: 16708071]

15. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180–184. [PubMed: 7920638]

16. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421–430. [PubMed: 26312828]

17. Berge G, Sando SB, Rongve A, Aarsland D, White LR. Apolipoprotein E 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry. 2014;85(11)1227–1231. [PubMed: 24639435]

18. Lovati C, Galimberti D, Albani D, et al. APOE ɛ2 and ɛ4 influence the susceptibility for Alzheimer's disease but not other dementias. Int J Mol Epidemiol Genet. 2010;1(3):193–200. [PubMed: 21537391]

19. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012; 8(1): 1–13. [PubMed: 22265587]

20. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8(12):1150–1157. [PubMed: 19909913]

21. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 Suppl):417–423. [PubMed: 16914880]

22. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–676. [PubMed: 18725592]

23. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015–2019. [PubMed: 7969952]

24. Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropcithol Exp Neurol. 2002;61(11):935–946.

25. Blauwendraat C, Faghri F, Pihlstrom L, et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging. 2017;57:247.e9–e247.e13.

26. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. [PubMed: 25722852]

27. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. [PubMed: 26432245]

28. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele epsi;4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 1994;44(10)1950–1950. [PubMed: 7936253]

29. Tsuang D, Leverenz JB, Lopez OL, et al. APOE ε4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurol. 2013;70(2):223. [PubMed: 23407718]

30. St Clair D, Norrman J, Perry R, Yates C, Wilcock G, Brookes A. Apolipoprotein E ε4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. Neurosci Lett. 1994; 176(1) :45–46. [PubMed: 7970234]

31. Singleton AB, Wharton A, O'Brien KK, et al. Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2002;14(4):167–175. [PubMed: 12411758]

32. Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–2193. [PubMed: 29878075]

33. Dickson DW, Heckman MG, Murray ME, et al. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91(12):e1182–e1195. [PubMed: 30143564]

34. Tulloch J, Leong L, Chen S, et al. APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement. 2018;14(7):889–894. [PubMed: 29544979]

35. Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association between APOE and Parkinson's disease. Neurobiol Dis. 2012;46(2):389–392. [PubMed: 22349451]

36. Ogaki K, Martens YA, Heckman MG, et al. Multiple system atrophy and apolipoprotein E. Mov Disord. 2018;33(4):647–650. [PubMed: 29442376]

37. Morris HR, Schrag A, Nath U, et al. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neurosci Lett. 2001;312(2):118–120. [PubMed: 11595348]

38. Morris HR, Vaughan JR, Datta SR, et al. Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. Neurology. 2000;55(12):1918–1920. [PubMed: 11134398]

39. Toji H, Kawakami H, Kawarai T, et al. No association between apolipoprotein E alleles and olivopontocerebellar atrophy. J Neurol Sci. 1998; 158(1):110–112. [PubMed: 9667788]

40. Sailer A, Scholz SW, Nalls MA, et al. A genome-wide association study in multiple system atrophy. Neurology. 2016;87(15):1591–1598. [PubMed: 27629089]

41. Kouri N, Ross OA, Dombroski B, et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 2015;6:7247. [PubMed: 26077951]

42. Zhao N, Liu C-C, Vanlngelgom AJ, et al. APOE ε2 is associated with increased tau pathology in primary tauopathy. Nat Commiin. 2018;9(1):4388.

43. Pickering-Brown SM, Owen F, Isaacs A, et al. Apolipoprotein E ε4 Allele Has No Effect on Age at Onset or Duration of Disease in Cases of Frontotemporal Dementia with Pick- or Microvacuolar-Type Histology. Exp Neurol. 2000; 163(2):452–456. [PubMed: 10833320]

44. Baba Y, Putzke JD, Tsuboi Y, et al. Effect of MAPT and APOE on prognosis of progressive supranuclear palsy. Neurosci Lett. 2006;405(1–2):116–119. [PubMed: 16839689]

45. Anouti A, Schmidt K, Lyons KE, et al. Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Neurology. 1996;46(4):1156–1157. [PubMed: 8780111]

46. Tabaton M, Rolleri M, Masturzo P, et al. Apolipoprotein E element 4 allele frequency is not increased in progressive supranuclear palsy. Neurology. 1995;45(9):1764–1765. [PubMed: 7675243]

47. Sawa A, Amano N, Yamada N, et al. Apolipoprotein E in progressive supranuclear palsy in Japan. Mol Psychiatry. 1997;2(4)341–342. [PubMed: 9246676]

48. Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699–705. [PubMed: 21685912]

49. Borroni B, Perani D, Archetti S, et al. Functional correlates of Apolipoprotein E genotype in Frontotemporal Lobar Degeneration. BMC Neurol. 2006;631.

50. Josephs KA, Tsuboi Y, Cookson N, Watt H, Dickson DW. Apolipoprotein E ε4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration. Arch Neurol. 2004;61(10):1579. [PubMed: 15477512]

51. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology. 1997;48(4):959–969. [PubMed: 9109885]

HIGHLIGHTS

- *APOE ε4* increases while *APOE ε2* decreases relative risk of developing AD and LBD.

- *APOE* does not alter risk of developing CBD, MSA, or PSP.

- *APOE ε4* decreases survival in a dose-dependent manner in AD and LBD.

Table 1:

Cohort characteristics and distribution of *APOE* genotypes in study populations

	Controls	AD	PD	CBD	LBD	MSA	PSP
N	591	571	348	41	525	223	202
Mean Age ± SD (years)[a]	71.7 ± 11.0	81.8 ± 10.1	78.2 ± 9.4	74.8 ± 9.3	77.5 ± 8.2	66.1 ± 10.8	78.1 ± 9.7
Age range (years)[a]	(50, 105)	(41, 103)	(19, 107)	(51, 96)	(49, 99)	(20, 90)	(55, 102)
No. Male (%)	318 (53.8)	221 (38.7)	234 (67.2)	18 (43.9)	338 (64.4)	109 (48.9)	113 (55.9)
No. Female (%)	273 (46.2)	350 (61.3)	114 (32.8)	23 (56.1)	187 (35.6)	114 (51.1)	89 (44.1)
No. Pathologically-confirmed	218 (36.9)	571 (100)	348 (100)	41 (100)	525 (100)	223 (100)	202 (100)
No. Clinically-defined	373 (63.1)[b]	N/A	N/A	N/A	N/A	N/A	N/A
No. with $\varepsilon2/\varepsilon2$ (%)	5 (0.8)	0 (0)	0 (0)	0 (0)	2 (0.4)	0 (0)	3 (1.5)
No. with $\varepsilon2/\varepsilon3$ (%)	83 (14.0)	29 (5.1)	54 (15.5)	4 (9.8)	35 (6.7)	25 (11.2)	20 (9.9)
No. with $\varepsilon2/\varepsilon4$ (%)	14 (2.4)	11 (1.9)	6 (1.7)	1 (2.4)	14 (2.7)	6 (2.7)	5 (2.5)
No. with $\varepsilon3/\varepsilon3$ (%)	368 (62.3)	208 (36.4)	203 (58.3)	28 (68.3)	239 (45.5)	141 (63.2)	138 (68.3)
No. with $\varepsilon3/\varepsilon4$ (%)	104 (17.6)	252 (44.1)	82 (23.6)	6 (14.6)	187 (35.6)	48 (21.5)	33 (16.3)
No. with $\varepsilon4/\varepsilon4$ (%)	17 (2.9)	71 (12.4)	3 (0.9)	2 (4.9)	48 (9.1)	3 (1.3)	3 (1.5)

[a] Age was defined as age at death for pathologically-confirmed samples and age at specimen collection for clinically-defined control samples. Age information was available for 590/591 controls, 568/571 AD samples, 342/348 PD samples, 41/41 CBD samples, 523/525 LBD samples, 101/223 MSA samples, and 202/202 PSP samples.

[b] DNA from clinically defined control samples was extracted from blood as opposed to brain tissue from all other cohorts.

Abbreviations: AD, Alzheimer's disease; PD, Parkinson's disease; CBD, corticobasal degeneration; LBD, Lewy body dementia; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; SD, standard deviation; N/A, not applicable.

Table 2:

Association of *APOE* *ε4* and *ε2* with risk of neurodegenerative diseases

Cohort	N	APOE ε4 carriers			APOE ε2 carriers		
		N. samples (%)[a]	OR (95% CI)	p value	No. samples (%)[b]	OR (95% CI)[c]	p value
Controls	591	135 (22.8)	1.00 (Reference)	N/A	102 (17.3)	1.00 (Reference)	N/A
AD	571	334 (58.5)	**4.13 (3.23, 5.26)**	**3.67×10^{-30}**	40 (7.0)	**0.21 (0.13, 0.34)**	**5.39×10^{-10}**
PD	348	91 (26.1)	1.18 (0.88, 1.59)	0.27	60 (17.2)	0.88 (0.60, 1.29)	0.52
CBD	41	9 (22.0)	1.10 (0.59, 2.04)	0.76	5 (12.2)	0.57 (0.20, 1.60)	0.29
LBD	525	249 (47.4)	**2.94 (2.34, 3.71)**	**6.60×10^{-20}**	51 (9.7)	**0.39 (0.26, 0.59)**	**6.88×10^{-6}**
MSA	223	57 (25.6)	1.11 (0.74, 1.67)	0.62	31 (13.9)	0.80 (0.43, 1.49)	0.48
PSP	202	41 (20.3)	0.95 (0.66, 1.35)	0.77	28 (13.9)	0.72 (0.45, 1.14)	0.16

ORs, 95% CIs, and p value results from logistic regression models adjusted for sex and age at collection for clinically-defined control samples or age at death for pathologically-confirmed samples.

[a] *ε4* allele carriers included individuals with genotypes *ε2/ε4*, *ε3/ε4*, and *ε4/ε4*.

[b] *ε2* allele carriers included individuals with genotypes *ε2/ε2*, *ε2/ε3* and *ε2/ε4*.

[c] When calculating the OR, individuals with the *ε2/ε4* genotype were excluded from the *ε2* relative risk analyses since *ε2* is predicted to be protective and *ε4* is shown to be a risk factor.

Abbreviations: AD, Alzheimer's disease; PD, Parkinson's disease; CBD, corticobasal degeneration; LBD, Lewy body dementia; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; OR, odds ratio; CI, confidence interval; N/A, not applicable.